Ginkgo Bioworks(us:DNA)
5.70
-4.36%
Updated on 2025-04-03
Open:5.50
Close:5.70
High:5.75
Low:5.44
Prev Close:5.96
Volume:1.45M
Turnover:8.16M
Turnover Ratio:2.50%
Shares:58.03M
MarketCap:330.79M
| Date | Total | Total Shares | Total Ratio | New | Increased | Decreased |
|---|---|---|---|---|---|---|
| 2024-06-30 | 378 | 23121713 | 1.11% | 49 | 67 | 178 |
| 2024-03-31 | 387 | 1271309961 | 61.95% | 57 | 109 | 146 |
| 2023-12-31 | 383 | 1253236836 | 62.62% | 43 | 108 | 143 |
| 2023-09-30 | 355 | 1217922261 | 61.74% | 54 | 137 | 73 |
| 2023-06-30 | 346 | 1192973580 | 61.03% | 41 | 119 | 102 |
| 2023-03-31 | 353 | 1125528741 | 58.20% | 42 | 101 | 128 |
| 2022-12-31 | 379 | 991263712 | 52.39% | 70 | 112 | 138 |
| 2022-09-30 | 360 | 930320438 | 56.44% | 73 | 103 | 109 |
| date | orgName | total | ratio | changeShares | changeRatio |
|---|---|---|---|---|---|
| 2024-06-30 | Viking Global Investors Lp | 3577128 | 0.17% | 0 | |
| 2024-06-30 | Vanguard Group Inc | 3474101 | 0.17% | 327684 | 10.41% |
| 2024-06-30 | Baillie Gifford & Co | 3360647 | 0.16% | -2464345 | -42.31% |
| 2024-06-30 | Anchorage Capital Group, L.L.C. | 1746365 | 0.08% | 0 | |
| 2024-06-30 | Blackrock Inc. | 1050271 | 0.05% | -771281 | -42.34% |
| 2024-06-30 | Two Sigma Advisers, Lp | 786089 | 0.04% | 757813 | 2680.06% |
| 2024-06-30 | Legal & General Group Plc | 675633 | 0.03% | 389688 | 136.28% |
| 2024-06-30 | Glenview Capital Management, Llc | 662500 | 0.03% | 62500 | 10.42% |
| 2024-06-30 | Sb Investment Advisers (Uk) Ltd | 610730 | 0.03% | 0 | |
| 2024-06-30 | Ark Investment Management Llc | 596280 | 0.03% | -4143893 | -87.42% |
About
Ginkgo Bioworks, Inc. is building a platform to enable customers to program cells as easily as we can program computers. Ginkgo’s platform is market agnostic and enables biotechnology applications across diverse markets, from food and agriculture to industrial chemicals to pharmaceuticals. Ginkgo is also actively supporting a number of biosecurity efforts to respond to COVID-19, including vaccine manufacturing optimization, therapeutics discovery, and K-12 pooled testing.
Address:27 Drydock Avenue,8th floor
Website:www.ginkgobioworks.com
Market Movers